Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.53 |
| ▸ | RORC | P51449 | 4/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15444714 | 0.87 | HTR3A (0.55) | HTR3ARORCFFAR4RAB9A | |
| SCHEMBL15440829 | 0.83 | HTR3A (0.54) | HTR3ARORCFFAR4RAB9A | |
| SCHEMBL23812510 | 0.83 | HTR3A (0.52) | HTR3ARORCFFAR4RAB9A | |
| SCHEMBL16516601 | 0.82 | RORC (0.43) | HTR3ARORCSCN9ASTAT1 | |
| SCHEMBL7421574 | 0.79 | SCN9A (0.58) | RORCSCN9ASTAT1 | |
| SCHEMBL3153838 | 0.78 | RAB9A (0.47) | HTR3AFFAR4RAB9A | |
| SCHEMBL23877758 | 0.77 | KDM4E (0.46) | HTR3ARORCSCN9ASTAT1 | |
| SCHEMBL16517332 | 0.76 | RORC (0.51) | RORCSCN9ASTAT1 | |
| SCHEMBL18131343 | 0.74 | RAB9A (0.47) | HTR3ARAB9ASCN9A | |
| SCHEMBL9024249 | 0.74 | ALDH1A1 (0.57) | RORCSCN9ASTAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312169-B1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-09-15 | — | — | EP | disclosed |
| US-10407443-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20180327421-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-10125145-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-13 | — | — | US | disclosed |
| EP-3312169-A1 | 5-HT3 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-20170260201-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9670229-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20160251373-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-9346829-B2 | 5-HT3 receptor antagonists | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20150182533-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-02 | — | — | US | disclosed |
| EP-2875011-A1 | 5-HT3 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-9012447-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-21 | — | — | US | disclosed |
| WO-2014014951-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20140024644-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407443-B2 | 5-HT3 receptor antagonists | HTR3A, HTR3B, HTR5A | HTR3A 1/4885RORC 3780/4885FFAR4 316/4885 |
| US-20170260201-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | HTR3A 1/4885RORC 3780/4885FFAR4 316/4885 |
| US-20150182533-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR3E | HTR3A 1/4885RORC 4377/4885FFAR4 275/4885 |
| US-20180327421-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | HTR3A 1/4885RORC 3780/4885FFAR4 316/4885 |
| US-20140024644-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | HTR3A 1/4885RORC 3780/4885FFAR4 316/4885 |
| US-20160251373-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | HTR3A 1/4885RORC 3780/4885FFAR4 316/4885 |
| US-10125145-B2 | 5-HT3 receptor antagonists | HTR3A, HTR3B, HTR5A | HTR3A 1/4885RORC 3780/4885FFAR4 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.